• Primidone (Mysoline) and Human Serum Paraoxonase-1 Inhibitio

  2026-05-19

  This study provides a quantitative analysis of how Primidone (Mysoline) and other antiepileptic drugs inhibit human serum paraoxonase-1 (hPON1) activity in vitro. The findings illuminate mechanistic interactions relevant for both clinical therapy and translational disease model research.

• E. coli Uracil-DNA Glycosylase (UDG): Technical Use & QC Gui

  2026-05-19

  E. coli Uracil-DNA Glycosylase (UDG) is designed to excise uracil from DNA, preventing PCR product contamination and supporting high-fidelity DNA amplification. Use this enzyme strictly for research workflows involving DNA, not for RNA, short oligonucleotides, or diagnostic applications.

• SM-164 (SKU A8815): Reliable Bivalent Smac Mimetic for Cance

  2026-05-18

  This article presents an evidence-based, scenario-driven analysis of SM-164 (SKU A8815), a bivalent Smac mimetic from APExBIO, addressing key laboratory challenges in apoptosis and cytotoxicity workflows. Drawing on literature and product data, it details how SM-164 enables reproducible, sensitive apoptosis induction in tumor cell models, supporting reliable caspase activation assays and advanced cancer research.

• Topotecan’s Role in Cancer Therapy: Pharmacology and Clinica

  2026-05-18

  The reference review details topotecan’s innovation as a water-soluble topoisomerase I inhibitor, highlighting its pharmacological features, clinical efficacy in refractory cancers, and safety profile. Its unique mechanism and non-cross-resistance underpin its value in combination regimens, while also informing translational research involving DNA-targeting chemotherapeutics.

• Chenodeoxycholic Acid: FXR-KLF11 Modulation and Translationa

  2026-05-17

  Explore the unique mechanistic insights of Chenodeoxycholic Acid (CDCA) in FXR-KLF11 pathway modulation. This article delivers an advanced, practical perspective on CDCA’s role in cholesterol metabolism research and renal protection, bridging molecular detail with translational assay implications.

• RNA Pol II Degradation Triggers Active Apoptosis in Cancer C

  2026-05-16

  Harper et al. (2025) reveal that inhibition of RNA polymerase II (Pol II) induces apoptosis through a regulated pathway independent of transcriptional loss. This discovery uncovers a distinct cell death mechanism, informing both mechanistic cancer research and the strategic use of apoptosis inducers such as bivalent Smac mimetics.

• Translational Strategies with Z-VAD-FMK: Apoptosis, Resistan

  2026-05-15

  This thought-leadership article bridges mechanistic insights, translational strategy, and the evolving landscape of apoptosis inhibition with Z-VAD-FMK. Drawing from recent literature, including antitumor innovation in EGFR-TKI-resistant NSCLC, we dissect the pivotal role of pan-caspase inhibition in experimental design and clinical translation. The discussion integrates competitive benchmarking, protocol optimization, and forward-looking perspectives for researchers navigating complex cell death pathways.

• OM-MSCs Reduce Golgi Stress via PI3K/Akt/mTOR After Stroke I

  2026-05-15

  This study demonstrates that olfactory mucosa mesenchymal stem cells (OM-MSCs) mitigate Golgi apparatus stress responses following cerebral ischemia/reperfusion injury (IRI) by activating the PEDF-PI3K/Akt/mTOR signaling pathway. The findings provide a mechanistic basis for neuroprotection, highlighting new avenues for targeting Golgi stress in stroke models.

• S63845 MCL1 Inhibitor: Precision Activation of Apoptosis Pat

  2026-05-14

  S63845 empowers hematological cancer research by enabling highly selective, nanomolar-scale modulation of the mitochondrial apoptotic pathway. This guide translates cutting-edge BH3-mimetic research into actionable workflows, troubleshooting advice, and comparative insights for optimizing BAX/BAK-dependent apoptosis studies.

• Biotin-16-UTP: Technical Guide for RNA Labeling Workflows

  2026-05-14

  Biotin-16-UTP is designed for efficient biotin labeling of RNA during in vitro transcription, enabling precise RNA detection, purification, and interaction studies. Researchers should use this reagent for workflows that require high-specificity streptavidin interactions; it is not suitable for diagnostic or clinical applications.

• AT-406 (SM-406): Precision IAP Targeting for Apoptosis Resea

  2026-05-13

  Discover how AT-406 (SM-406) enables robust, quantifiable apoptosis pathway activation in cancer cells through precision IAP antagonism. This article uniquely bridges advanced mechanistic insight with practical assay design, offering researchers actionable guidance for oncology studies.

• DRB and the Future of Cell Fate Control in Translational Res

  2026-05-13

  This article examines 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) as a precision tool for translational researchers. By interweaving mechanistic insights on transcriptional elongation inhibition, cyclin-dependent kinase signaling, and phase separation-driven cell fate transitions, it establishes DRB’s place at the intersection of stem cell engineering and antiviral research. Key evidence—including recent findings on the IkB-NF-kB-CCND1 axis—supports actionable recommendations, protocol nuances, and strategic guidance for next-generation biomedical workflows. The narrative directly addresses how APExBIO’s high-purity DRB advances the field beyond conventional product literature.

• WEHI-539: Advanced BCL-XL Inhibitor Workflows for Apoptosis

  2026-05-12

  WEHI-539 stands out as a selective BCL-XL inhibitor, enabling precise dissection of apoptotic resistance and cancer stem cell sensitization. This article delivers workflow enhancements, troubleshooting insights, and experimental guidance for maximizing its utility in apoptosis and chemoresistance studies.

• EGCG Nanoparticles Enhance FLASH-RT Efficacy via DNA Damage

  2026-05-12

  This study demonstrates the use of functionalized EGCG nanoparticles (BENPs) to significantly boost the antitumor effect of ultra-high dose rate radiotherapy (FLASH-RT) by increasing DNA damage and stimulating antitumor immunity. The work provides mechanistic insight and practical benchmarks for integrating radiosensitizers with advanced radiotherapy protocols.

• Cyclophosphamide: Applied Workflows in Cancer Research

  2026-05-11

  Cyclophosphamide empowers rigorous apoptosis induction and immune modulation in cancer research and transplantation models. Discover optimized protocols, troubleshooting insights, and comparative advantages that enhance reproducibility and translational impact for oncology and immunology workflows.

16675 records 2/1112 page Previous Next 12345 下5页 Last page